Robaxin and Xith nerve paralysis - a phase IV clinical study of FDA data

Summary:

We study 8,362 people who take Robaxin or have Xith nerve paralysis. No report of Xith nerve paralysis is found in people who take Robaxin.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Sep, 25, 2022

No report is found.


What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 8,358 Robaxin users for its effectiveness, alternative drugs and more.

What is Xith Nerve Paralysis?

Xith nerve paralysis (damage or swelling of the facial nerve resulting dysfunction) is found to be associated with 13 drugs and 4 conditions by eHealthMe.

Do you take Robaxin and have Xith nerve paralysis?

Check whether Xith nerve paralysis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Xith nerve paralysis and when was it recovered:

Expand to all the drugs that have ingredients of methocarbamol:

Alternative drugs to, pros and cons of Robaxin:

Xith nerve paralysis treatments and more:

COVID vaccines that are related to Xith nerve paralysis:

All the drugs that are associated with Xith nerve paralysis:

All the conditions that are associated with Xith nerve paralysis:

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: